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S U M M A R Y
Monocytes play important roles in the inﬂammatory response, which is essential for the innate response
to pathogens. Monocytes are able to differentiate to dendritic cells (DCs) under inﬂammatory situations.
In recent decades, the heterogeneity of monocytes and their different trafﬁc pathways have been
identiﬁed in both human and murine systems. Different monocyte subsets show distinct inﬂammatory
cytokine proﬁles and differentiation potential under steady-state and inﬂammatory situations. We
discuss the biology of monocytes, their relationship with DCs, and the potential of monocyte-derived
dendritic cells (moDCs) in the design of vaccines against certain chronic infectious diseases.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id
Open access under CC BY-NC-ND license.1. Introduction
Monocytes are circulating blood leukocytes with a fundamental
capacity to differentiate into macrophages. In the right environ-
ment, monocytes can also differentiate into specialized antigen-
presenting dendritic cells (moDCs). In the human and in mice,
monocytes have some typical morphological features: irregular
cell shape, oval- or kidney-shaped nucleus, cytoplasmic vesicles,
and a high cytoplasm-to-nucleus ratio. However, they are still very
heterogeneous in size and shape and are difﬁcult to distinguish by
morphology or by light scatter analysis alone from blood DCs,
activated lymphocytes, and natural killer (NK) cells. In recent
decades, with the help of ﬂow cytometry and different transgenic
mouse models, monocytes have been divided into two to three
subsets.1–3
Monocytes play important roles in the inﬂammatory response,
which is essential for the innate response to pathogens. They are
distinct from polymorphonuclear cells (PMNs) and NK cells, which
also belong to the innate arm of the immune system, as well as
from lymphoid T and B cells, which represent the adaptive arm of* Corresponding author. Tel.: +86 10 8778 8420.
E-mail address: quchf@cicams.ac.cn (C. Qu).
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http://dx.doi.org/10.1016/j.ijid.2013.09.023the immune system. Monocytes represent about 10% of leukocytes
in human blood and 4% of leukocytes in mouse blood. In recent
years, studies using murine models have clearly demonstrated that
monocytes are distinct from conventional dendritic cells (cDCs),
which are derived from dendritic cell precursors present in the
bone marrow and circulating blood.4,5 Monocytes are also distinct
from plasmacytoid dendritic cells (pDCs), the type I interferon-
producing cells, which are differentiated from the hematopoietic
precursors in the bone marrow and trafﬁc into lymphoid organs via
high vein endothelium cells.
In some infections, monocyte numbers increase in peripheral
blood, and they inﬁltrate into the inﬂammatory sites. Studies on
monocytes have broadened our horizons on dendritic cell biology in
relation to the induction of innate and adaptive immune responses.
In recent decades, heterogeneity among monocytes and their
different trafﬁc pathways have been identiﬁed. The inﬂammatory
cytokine proﬁles and differentiation potentials of different mono-
cyte subsets under steady-state and inﬂammatory situations in
response to distinct microbial products are recognized. This progress
has provided opportunities for novel designs of new treatments
against pathological inﬂammation, as well as prophylactic and
therapeutic vaccines against some chronic diseases.
2. Monocyte phenotypic heterogeneity: human PBMCs
More than 20 years ago, Passlick et al. demonstrated that
human monocytes in the blood are heterogeneous.6 In addition toociety for Infectious Diseases. Open access under CC BY-NC-ND license.
C. Qu et al. / International Journal of Infectious Diseases 19 (2014) 1–52the classical CD14++ monocytes, which comprise the major subset
in the circulation, a subset of CD14+CD16+ monocytes is readily
identiﬁed, which make up 2.2% of the whole peripheral blood
mononuclear cells (PBMCs) and form about 13% of all CD14-
positive cells.6 The CD14++CD16monocytes represent 80% to 90%
of blood monocytes. Recently, new nomenclature has been
suggested by an expert panel in Brescia, Italy, to deﬁne three
subsets of monocytes according to the cell surface expression of
CD14 and CD16. The major subset of monocytes consists of CD14-
high CD16-negative (CD14++CD16). The CD16 expressing mono-
cytes are usually divided into CD14-high CD16-low (CD14++CD16+)
and a CD14-low CD16-high (CD14+CD16++) subsets.3
Human CD14++ CD16 monocytes express high levels of CCR2
(C-C chemokine receptor 2) and CD62L (L-selectin), but lower
CX3CR1 (C-X3-C chemokine receptor 1) on their surface. They have
higher phagocytic and myeloperoxidase activity, and superoxide
release. When stimulated with lipopolysaccharide (LPS), the cells
produce higher levels of interleukin (IL)-10, but lower levels of
tumor necrosis factor alpha (TNF-a) and IL-1. In contrast, human
CD16+ monocytes express high levels of CX3CR1, but lower CCR2,
and are responsible for the production of TNF-a in response to LPS
stimulation.7–10 Several studies have reported that CD16+ mono-
cytes are found in larger numbers in the blood of patients with
acute inﬂammation and infectious diseases.11,12 The numbers of
CD16+ cells have been found to increase greatly in the organs
involved in some autoimmune diseases, such as rheumatoid
arthritis and systemic lupus.13,14
Regarding the relationship to moDCs, both subsets of mono-
cytes can differentiate into dendritic cells (DCs) in the presence of
granulocyte-macrophage colony-stimulating factor (GM-CSF) and
IL-4 when cultured in vitro. They internalize soluble and
particulate antigens similarly, and both are able to stimulate T
cell proliferation in autologous and allogeneic cultures.7,15,16
However, CD16+ moDCs express higher levels of CD86, CD11a,
and CD11c, and show lower expression of CD1a and CD32
compared to CD16moDCs. LPS-stimulated CD16moDCs express
increased levels of IL-12 p40 mRNA and secrete greater amounts of
IL-12 p70 than CD16+ moDCs, whereas levels of transforming
growth factor beta 1 (TGF-b1) mRNA are higher in CD16+ moDCs.
Moreover, CD4+ T cells stimulated with CD16+ moDCs secrete
increased amounts of IL-4 compared to those stimulated by CD16
moDCs.7 Using an in vitro transendothelial migration model,
Randolph et al. showed that monocytes can migrate across an
endothelial barrier in vitro and differentiate into DCs, which
reverse-migrate back across the endothelial layer, or into
macrophages, which remain in the subendothelial matrix.17 In
this model, the CD14+CD16+ monocytes were found to be more
likely to become DCs than the CD14+CD16monocytes,8 indicating
that the CD14+CD16+monocytes might be precursors of DCs. There
appears to be a developmental relationship in that the classical
CD14+ monocytes develop the non-classical CD14+CD16+ mono-
cytes. CD14+CD16+ monocytes may represent a more mature
version.8
3. Monocyte phenotypic heterogeneity: mouse PBMCs
To study the roles and functions of different monocyte subsets
under physiological or pathological situations, CD14 does not serve
as a practical marker for identifying mouse blood monocytes, as in
humans, because CD14 levels are very low on the cell surface of
mouse monocytes.1 The expression of macrophage colony-
stimulating factor receptor (M-CSFR, CD115), a key factor in
driving the development of macrophages,18 selectively delineates
monocytes in the blood of mice. The use of CD115 alone or in
combination with F4/80 identiﬁes the same subsets of monocytes
in wild-type C57BL/6 mice19 as does the use of GFP knocked intothe CX3CR1 locus,20 a popular model for tracing monocytes
through an endogenous ﬂuorescent tag. Currently murine periph-
eral blood monocytes are divided into at least two subsets: the Gr1
(Ly6C) high and Gr1 (Ly6c) low monocytes. The mouse Ly6Chigh
monocytes are also CCR2+CD62L+CX3CR1
low, and correspond to
CD14++CD16 (classic) human monocytes. Ly6clow monocytes
express higher levels of CX3CR1, and the CX3CR1
highCCR2+/
CD62LLy6clow mouse monocytes correspond to CD14+CD16+
human monocytes.19,21,22 A subset expressing Gr1 (Ly6C)int has
also been reported.19,23 BM monocytes are Ly6chigh and that Ly6c
expression is rapidly lost during in vitro development into
macrophages or DCs.24 When sorted Ly6chigh blood monocytes
were cultured in vitro, expression of Ly6C was lost within 3 days.
On depleting mouse blood monocytes, the Ly6chigh cells had
repopulated in 3–4 days, with Ly6clow/int cells appearing in
signiﬁcant numbers from 7 days after the depletion.24 This
possibly mimics the developmental relationship in the maturation
process of monocytes.
4. Differentiation of the DC progenitor: origin of DC subsets
DCs comprise several subsets, and their roles in the presenta-
tion of antigens derived from pathogens, vaccines, and self-tissues
are now being elucidated (see the review by Villadangos and
Schnorrer25). Different DC types have distinct roles in initiating
immunity to speciﬁc pathogens. There are two main categories of
DCs: pDCs and conventional DCs (cDCs). They both originate from
hematopoietic stem cells in the bone marrow via intermediate
progenitors.
pDCs generate high amounts of type I interferon (IFN-I) and
acquire the typical DC morphology after activation. Their activa-
tion and IFN-I production are critical for the initiation of antiviral
immune responses. It has been shown that the basic helix-loop-
helix protein E2-2/TCF4 is a required transcription factor for pDC
development in both the human and the mouse26 and for the
maintenance of mature pDCs.27 Recently, a population identiﬁed in
the bone marrow as Lin c-Kitint/loFlt3+M-CSFR and expressing
high amounts of E2-2 has been described as the pDC progenitor.
These cells are derived from either common DC progenitors (CDPs)
or lymphoid-primed multi-potent progenitors, with prominent
pDC differentiation potential.28 The pDC-committed progenitors
are different from the macrophage and DC progenitors (MDP),
which express the phenotypic markers as Lin CX3CR1
+CD11b c-
Kitint/loFlt3+M-CSFR+ and produce many more cDCs than pDCs.29,30
cDCs present in the thymus, spleen, and lymph nodes and can
be grouped into two main categories that are distinguished by the
paths they follow to access the lymphoid organs.31 One major
category of lymphoid organ DCs is the blood-derived or resident
DCs. With their surface expression of CD4 and CD8, the lymphoid
organ resident DCs can be subdivided into three types: CD4+ DCs,
CD8+ DCs, and CD4CD8 (double-negative) DCs. They develop
from bone marrow precursors within the lymphoid organs without
previously trafﬁcking through peripheral tissues.32–35 The migra-
tory DCs are the second category of lymph node DCs, and these
develop from earlier precursors in the peripheral tissues and travel
through the afferent lymphatics to reach the local draining lymph
nodes. This group of DCs is largely absent from the spleen and
thymus because these organs do not receive afferent lymph.25
Migratory DCs follow the lifecycle described by the Langerhans cell
paradigm: they trafﬁc from peripheral tissues to the lymph nodes,
where they exhibit a mature phenotype.31 They are present in
peripheral tissues in an immature state that is specialized for
sampling the environment using various endocytic mechanisms,
but are characterized by low levels of expression of MHC molecules
and T cell co-stimulatory molecules (see the review by
Steinman36).
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inﬂammatory conditions in peripheral tissues
In the bone marrow, a common monocyte DC precursor29 gives
rise to monocytes and other precursors termed common DC
precursors and pre-cDCs.30,35,37 Pre-cDCs move into the blood to
seed both lymphoid and non-lymphoid tissues forming CD11chigh,
MHC-IIhigh DCs.35 DCs in the steady-state are dependent upon the
hematopoietin, Flt3 ligand (Flt3L), whereas monocytes require
macrophage colony-stimulating factor (M-CSF).38–40 Most DCs in
the steady state are independent of monocytes.33,41
However, as early as the 1990s, Sallusto and Lanzavecchia15 and
Romani et al.16 demonstrated that human monocytes differentiate
into DCs in vitro by culturing with GM-CSF and IL-4. Injection of
moDC pulsed exogenous antigens rapidly expands human T cell
immunity.42 moDCs pulsed with certain tumor-associated anti-
gens can frequently expand tumor-speciﬁc cytotoxic T lympho-
cytes (CTLs) and elicit regression even in advanced cancer.43,44 In
order to study the biology of DCs, their roles in immune responses,
and their potential use for the treatment of certain diseases, several
methods to generate mouse DCs in vitro have been described
(reviewed by Shortman and Naik45). The GM-CSF in vitro cultured
DC is the most common DC type used in studies of mouse and
human DC biology, and for immunotherapy using DC vaccines.45
The differentiation of monocytes in vivo46 and under mimicked
physiological conditions47 has further been conﬁrmed. Recent
studies indicate that DCs in lymphoid organs have distinct origin
from DCs in non-lymphoid organs. Monocytes are precursor of
peripheral non-lymphoid organ DCs33,48–50 and the migratory DCs
under inﬂammatory conditions.19,41 However, within steady-state
lymph nodes, tissue-derived migratory DCs are found to be minor
constituents.41
6. Regulation of monocyte differentiation into dendritic cells
versus macrophages
The differentiation to DCs versus macrophages is regulated by
transcription factors and the cytokines they encounter. moDCs are
a crucial reservoir of specialized antigen-presenting cells (APCs)
that are recruited in the immune responses to certain micro-
organisms and potentially have an emergency back-up role in
cases of acute inﬂammation. moDCs express CD11b, CD11c, MHC-
II, dendritic cell-speciﬁc intercellular adhesion molecule-3-grab-
bing non-integrin (DC-SIGN), CD24, and CD172a, and they also
express macrophage markers CD107b and LAMP2.
PU.1 has been found to absolutely essential for the generation of
all cDCs and pDCs both in vivo under steady-state and in Flt3L -
containing cultures. It is also required for GM-CSF-induced DC
differentiation from early hematopoietic progenitors.51 However,
the role of PU.1 in moDC formation in vivo remains unclear. Ikaros
and growth factor independent 1 (GFI1) are also involved in DC
development. GFI1 is a crucial modulator of DC versus macrophage
development. GFI1-deﬁcient hematopoietic progenitor cells are
unable to develop into DCs in vitro in the presence of either Flt3L or
GM-CSF, and instead differentiate into macrophages. The other
transcription factors for different subsets of DCs are reviewed by
Merad et al.52
Some transcription factors favor the development of macro-
phages. Monocyte-derived macrophages express high levels of
MafB and only moderate levels of PU.1, and constitutive MafB
expression inhibits moDC differentiation. The balance between
MafB and PU.1 speciﬁes the differentiation to either macrophage or
DC.53
Cytokines that control the DC lineage commitment and
differentiation include Flt3L, M-CSF, GM-CSF, lymphotoxin beta,
and TGF-b1. Flt3L is a key regulator of DC commitment inhematopoiesis. Flt3 is the only molecule that interacts with Flt3L.
Loss of Flt3 expression in hematopoietic progenitors correlates
with the loss of DC differentiation potential. However, Flt3 is
absent from moDCs.54 M-CSF regulates the survival, proliferation,
and differentiation of macrophages.55 Its receptors (also named
CD115) are expressed on GMPs, MDPs, monocytes, and macro-
phages. In non-lymphoid tissues, colony-stimulating factor 1
receptor (CSF1R) regulates the differentiation or survival of CD11b+
cDCs. In addition to CSF1, IL-34 shows high afﬁnity for CSF1R.56
Skin keratinocytes produce high levels of IL-34, which favors
epidermal LCs but not dermal macrophages.57 CSF2 (GM-CSF)
controls the differentiation of the myeloid lineage and to date
remains a key cytokine for generating DC-based vaccines for
clinical use. It binds speciﬁcally to CSF2R, a heterodimer composed
of CSF2Ra and CSF2Rb, which are expressed on GMPs, MDPs, CDPs,
and some DC subsets: CD8+, CD103+, and CD11b+ cDCs. CSF2
regulates cDC survival and maturation, and the acquisition of the
capacity to cross-present antigens in non-lymphoid tissues
controls CD103 expression on tissue cDCs.
7. Role of monocyte-derived dendritic cells in antigen
presentation
The discovery of Toll-like receptors (TLRs) as components that
recognize conserved structures in pathogens has greatly advanced
understanding of how the body senses pathogen invasion, triggers
innate immune responses, and primes antigen-speciﬁc adaptive
immunity.58 Monocytes express abundant different types of TLRs
and patrol various tissues for signs of infection and inﬂammation;
they are approximately 20 times more abundant than DCs in blood
and bone marrow.59 The recruitment of monocytes to sites of
inﬂammation is critical for host defense and is regulated by
chemokines.60,61 Monocyte chemoattractant proteins (MCPs) are
critical to attract cells through activation of their cognate receptor
CCR2, which is expressed on the monocyte surface.62 The
mobilization of monocytes has been shown to have a critical role
in inducing immunity.63,64 The current literature demonstrates
that monocytes mainly serve as precursors for potent antigen-
presenting DCs in peripheral organs, and in particular during
inﬂammation. Following antigen capture, the migration with
MHC/peptide complexes to downstream lymph nodes gives them a
crucial role in the presentation of the antigen to T cells.65–69 Hence,
the mobilization of this monocyte reservoir in vivo to generate
potent antigen-presenting DCs can be a good target for the design
of vaccines against certain infectious diseases.
The roles of monocytes in antigen presentation have recently
been elucidated using microbial infection and TLR agonists that
mimic certain types of microbial infection. The infection of
monocytes directly by live or UV-inactivated inﬂuenza A virus
has been shown to promote their differentiation into CD83+CCR7+
DCs. The differentiated monocyte-derived DCs efﬁciently pre-
sented the antigens that they acquired to naı¨ve and to memory T
cells.70 When microbeads were injected into mice via intradermal
injection, Gr1high monocytes efﬁciently carried the antigen
message back into the local draining lymph nodes.19,46 Mono-
cyte-derived DCs formed at the infection site are crucial in
efﬁciently cross-priming the T cells in vivo.64–68,71 When the
antigen-presenting capacity of the monocyte subsets was tested in
vitro, human CD16+ monocytes10 and their mouse counterparts19
showed enhanced capacity for driving allogeneic T cell prolifera-
tion. By using DC-SIGN/CD209 as the marker to distinguish moDCs
from the other types of DC, Cheong et al. recently reported that
after the monocytes had differentiated into moDCs cultured with
GM-CSF their TLR4 and TLR7 expression increased. However, they
demonstrated that only injection of LPS, the natural ligand of TLR4,
administrated intravenously, increased the numbers of moDCs in
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with monocyte surface CD14 efﬁciently promoted monocyte
differentiation into moDCs.69 The fully differentiated moDCs
efﬁciently presented the soluble and cell-associated antigens to
T cells and showed better stimulating capacity than that of CD8+
DCs.69 We also found that the moDCs have the capacity to directly
cross-present the cell-associated antigens to naı¨ve T cells, as well
transfer the MHC-I/peptides to lymph organ resident DCs. The
effect of cross-priming was enhanced in the presence of antigen-
bound TLR7/8 agonists in inducing CD8+ T cell priming and
activation.68 Most recent studies have suggested that multiple DC
populations may be comparably effective at presenting exogenous
antigens to CD8+ T cells as long as the antigen is delivered to early
endocytic compartments.72,73
8. Perspective: moDCs, the potential targets for vaccine design
Vaccination is the most cost-effective approach for the control
of infectious diseases. Adjuvants are critical for puriﬁed protein
vaccines in order to stimulate optimal immune responses to them.
One of the important approaches in vaccination strategies is to
target the DCs in vivo by improving the antigen presentation and
activation of CD4+ and CD8+ T cells. The best protection of vaccine-
mediated immunity is likely to be elicited by the combination of
strong humoral and cell-mediated immune responses.74 Peripher-
al blood monocytes constitute an important pool of migratory DCs
in draining lymph nodes under inﬂammatory conditions. moDCs
that are formed de novo are essential for T cell immunity against
invading pathogens.64 Signaling pathways of TLRs expressed by
these cells, through recognition of various pathogen-associated
molecular patterns (PAMPs), induce these cells to secrete distinct
cytokines, which in turn, inﬂuence T cell differentiation. Therefore,
moDCs are important players in the development of an adaptive
immune response and they are important targets for vac-
cines.59,75,76 We have reported that human monocytes differenti-
ated into potent APCs after they phagocytozed dead cells
containing ssRNA, the TLR7/8 agonist, and induced strong CD8+
T cell responses to the cell-associated antigens.68 In a further study
we demonstrated that TLR8 agonists stimulate newly recruited
monocyte-derived cells into potent APCs that enhance hepatitis B
surface antigen immunogenicity in both humans and mice.77 Thus,
moDCs are important targets for the design of novel vaccines in the
control of infectious diseases.
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